Cartherics Pty Ltd Revenue and Competitors
Employee Data
- Cartherics Pty Ltd has 32 Employees.
- Cartherics Pty Ltd grew their employee count by 3% last year.
Cartherics Pty Ltd's People
Name | Title | Email/Phone |
---|
Cartherics Pty Ltd Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $95.5M | 616 | -23% | N/A | N/A |
#2 | $34.7M | 224 | N/A | N/A | N/A |
#3 | $14.7M | 81 | 4% | N/A | N/A |
#4 | $15.8M | 94 | 12% | N/A | N/A |
#5 | $16.9M | 104 | 17% | N/A | N/A |
#6 | $22.5M | 142 | 19% | N/A | N/A |
#7 | $19.5M | 88 | -15% | N/A | N/A |
#8 | $10.4M | 67 | -29% | N/A | N/A |
#9 | $9.7M | 84 | -14% | $412.3M | N/A |
#10 | $24.2M | 137 | 7% | N/A | N/A |
What Is Cartherics Pty Ltd?
Cartherics is a biotechnology company focused on developing innovative cancer therapies. \nWe work to create precisely-defined immunotherapy treatments to combat a variety of cancers. We take a multi-platform approach combining the best components of immune defences utilising gene editing and CAR technology – developing more precise and more accessible treatment options for patients. \n\nWe are focused on solid tumours and disrupting the tumour microenvironment (TME) to make tumours accessible to immune destruction.\n\nOur team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.\n\nWe’re developing new forms of solid cancer care treatment - helping patients fight cancer and take back control of their lives.
keywords:N/AN/A
Total Funding
32
Number of Employees
N/A
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 45 | 55% | N/A |
#2 | N/A | 58 | 21% | N/A |
#3 | $5M | 65 | 27% | N/A |
#4 | N/A | 67 | 68% | N/A |
#5 | N/A | 70 | 52% | N/A |